

**APPENDIX C**

Claim Text	Origin
<p><b>55. [A combination of Claims 5 and 47 (including the limitations of the claim(s) from which they depend) of the '625 application</b></p> <p>A vaccine which protects a pig against a porcine reproductive and respiratory syndrome (PRRS), comprising an effective amount of a biologically-pure virus</p> <p>selected from the group consisting of ISU-51 (VR 2429), ISU-55 (VR 2430), ISU-3927 (VR 2431), and ISU-1894 (VR 2475),</p> <p>or a virus exhibiting the identifying characteristics of a virus in said group,</p> <p>wherein said virus is attenuated; and</p> <p>a physiologically-acceptable carrier,</p> <p>wherein said virus is prepared by serial passage</p> <p>in a cell line selected from the group consisting of PSP-36, PSP-36-SAH, and MA-104.</p>	<p><b><u>Claim 45</u></b> A vaccine which protects a pig against a porcine reproductive and respiratory syndrome (PRRS) comprising an effective amount of the biologically pure virus of Claim 43...</p> <p><b><u>Claim 43</u></b> The biologically pure virus of Claim 42, selected from the group consisting of ISU-51 (VR 2429), ISU-55 (VR 2430), ISU-3927 (VR 2431) and ISU-1894, . . .</p> <p><b><u>Claim 42</u></b> A biologically pure virus selected from the group consisting of ISU-51 (VR 2429), ISU-55 (VR 2430), ISU-3927 (VR 2431) and ISU-1894; or a virus exhibiting the identifying characteristics of a virus in said group</p> <p><b><u>Claim 46</u></b> The vaccine of Claim 46, wherein said virus is live, inactivated or attenuated.</p> <p><b><u>Claim 45</u></b> . . . and a physiologically acceptable carrier.</p> <p><b><u>Claim 47</u></b> The vaccine of Claim 46, wherein said virus is attenuated and is prepared by serial passage in cell culture.</p> <p><b><u>Claim 5</u></b> The vaccine of Claim 1, wherein said vaccine is prepared from a virus cultured in a cell line selected from the group consisting of PSP-36, PSP-36-SAH and MA-104.</p>